Literature DB >> 23433128

The influence of PSA-RNA yield on the analysis of expressed prostatic secretions (EPS) for prostate cancer diagnosis.

Christopher Whelan1, Laura Crocitto, Mark Kawachi, Kevin Chan, David Smith, Timothy Wilson, Steven Smith.   

Abstract

INTRODUCTION: In patients with prostate cancer, luminal prostate-specific antigen (PSA) enters the circulation because the basement membrane and glandular epithelium are damaged. Given that excess mobilization of prostate cells during prostatic massage can influence normalization in diagnostic testing, we studied PSA mRNA levels in expressed prostatic secretions (EPS) from patients undergoing biopsy for prostate cancer to determine if prostate cells are preferentially mobilized from patients with prostate cancer during prostatic massage.
MATERIALS AND METHODS: Quantitative Reverse-Transcription PCR (qRT-PCR) was used to measure the RNA levels of GAPDH, PSA, TMPRSS2:ERG and PCA3 in EPS specimens obtained from patients undergoing biopsy for prostate cancer.
RESULTS: The level of PSA mRNA is significantly elevated in EPS specimens obtained from patients with a subsequent diagnosis of prostate cancer. This correlation influenced diagnostic testing results from EPS in two ways. First, when used as an exclusion parameter it appears to improve the diagnostic performance of TMPRSS2:ERG in EPS. Second, when used as a normalization parameter it appears to decrease the performance of these same tests.
CONCLUSION: When comparing the results of mRNA based prostate cancer diagnostics in EPS it will be essential to consider PSA mRNA as a prostate specific gene and not a housekeeping gene.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23433128      PMCID: PMC3936670     

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  13 in total

Review 1.  Molecular markers for prostate cancer.

Authors:  Mark A Reynolds; Kumar Kastury; Jack Groskopf; Jack A Schalken; Harry Rittenhouse
Journal:  Cancer Lett       Date:  2007-02-15       Impact factor: 8.679

2.  APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.

Authors:  Jack Groskopf; Sheila M J Aubin; Ina Lim Deras; Amy Blase; Sharon Bodrug; Craig Clark; Steven Brentano; Jeannette Mathis; Jimmykim Pham; Troels Meyer; Michelle Cass; Petrea Hodge; Maria Luz Macairan; Leonard S Marks; Harry Rittenhouse
Journal:  Clin Chem       Date:  2006-04-20       Impact factor: 8.327

3.  Molecular PCA3 diagnostics on prostatic fluid.

Authors:  Martijn P M Q van Gils; Erik B Cornel; Daphne Hessels; W Pim Peelen; J Alfred Witjes; Peter F A Mulders; Harry G Rittenhouse; Jack A Schalken
Journal:  Prostate       Date:  2007-06-01       Impact factor: 4.104

4.  Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.

Authors:  Bharathi Laxman; Scott A Tomlins; Rohit Mehra; David S Morris; Lei Wang; Beth E Helgeson; Rajal B Shah; Mark A Rubin; John T Wei; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2006-10       Impact factor: 5.715

5.  Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results.

Authors:  Laura E Crocitto; Darlynn Korns; Leo Kretzner; Taras Shevchuk; Sarah L Blair; Timothy G Wilson; Soroush A Ramin; Mark H Kawachi; Steven S Smith
Journal:  Urology       Date:  2004-10       Impact factor: 2.649

6.  DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.

Authors:  Daphne Hessels; Jacqueline M T Klein Gunnewiek; Inge van Oort; Herbert F M Karthaus; Geert J L van Leenders; Bianca van Balken; Lambertus A Kiemeney; J Alfred Witjes; Jack A Schalken
Journal:  Eur Urol       Date:  2003-07       Impact factor: 20.096

7.  Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.

Authors:  Jarrod P Clark; Kristofer W Munson; Jessie W Gu; Katarzyna Lamparska-Kupsik; Kevin G Chan; Jeffrey S Yoshida; Mark H Kawachi; Laura E Crocitto; Timothy G Wilson; Ziding Feng; Steven S Smith
Journal:  Clin Chem       Date:  2008-10-23       Impact factor: 8.327

Review 8.  Biology of prostate-specific antigen.

Authors:  Steven P Balk; Yoo-Joung Ko; Glenn J Bubley
Journal:  J Clin Oncol       Date:  2003-01-15       Impact factor: 44.544

9.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

10.  Recovery of bisulfite-converted genomic sequences in the methylation-sensitive QPCR.

Authors:  Kristofer Munson; Jarrod Clark; Katarzyna Lamparska-Kupsik; Steven S Smith
Journal:  Nucleic Acids Res       Date:  2007-04-16       Impact factor: 16.971

View more
  3 in total

1.  Urine stabilization and normalization strategies favor unbiased analysis of urinary EV content.

Authors:  Riccardo Vago; Giorgia Radano; Davide Zocco; Natasa Zarovni
Journal:  Sci Rep       Date:  2022-10-21       Impact factor: 4.996

2.  Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models.

Authors:  Christopher Whelan; Mark Kawachi; David D Smith; Jennifer Linehan; Gail Babilonia; Rosa Mejia; Timothy Wilson; Steven S Smith
Journal:  J Urol       Date:  2013-05-10       Impact factor: 7.450

3.  Molecular analyses of prostate tumors for diagnosis of malignancy on fine-needle aspiration biopsies.

Authors:  Menglin Shan; Qianlin Xia; Dong Yan; Yanjun Zhu; Xuan Zhang; Guihong Zhang; Jianming Guo; Jun Hou; Weiping Chen; Tongyu Zhu; Xiaoyan Zhang; Jianqing Xu; Jin Wang; Tao Ding; Jianghua Zheng
Journal:  Oncotarget       Date:  2017-11-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.